FULC Fulcrum Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FULC

Price (delayed)

$3.81

Market cap

$290.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.21

Enterprise value

$246.41M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 7
Highlights
The debt has contracted by 30% YoY and by 10% from the previous quarter
The equity has grown by 45% YoY but it has contracted by 7% from the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 30% YoY but it has decreased by 8% from the previous quarter
Fulcrum Therapeutics's net income has decreased by 16% YoY and by 12% from the previous quarter
The company's EPS fell by 5% QoQ and by 2.5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fulcrumtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of FULC

FULC stock price

How has the Fulcrum Therapeutics stock price performed over time
Intraday
-0.78%
1 week
0.53%
1 month
-0.52%
1 year
-48.16%
YTD
-66.31%
QTD
4.1%

Financial performance

How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$96.05M
Net income
-$85M
Gross margin
N/A
Net margin
N/A
Fulcrum Therapeutics's net income has decreased by 16% YoY and by 12% from the previous quarter
The company's operating income fell by 13% YoY and by 11% QoQ

Price vs fundamentals

How does FULC's price correlate with its fundamentals

Growth

What is Fulcrum Therapeutics's growth rate over time

Valuation

What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
0.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 5% QoQ and by 2.5% YoY
FULC's P/B is 54% below its 5-year quarterly average of 1.8 and 49% below its last 4 quarters average of 1.6
The equity has grown by 45% YoY but it has contracted by 7% from the previous quarter

Efficiency

How efficient is Fulcrum Therapeutics business performance
Fulcrum Therapeutics's ROE has increased by 8% YoY but it has decreased by 2.5% from the previous quarter
Fulcrum Therapeutics's ROA has increased by 6% YoY but it has decreased by 3.4% from the previous quarter
FULC's return on invested capital is down by 2.7% year-on-year

Dividends

What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FULC.

Financial health

How did Fulcrum Therapeutics financials performed over time
FULC's total assets is up by 42% year-on-year but it is down by 7% since the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 30% YoY but it has decreased by 8% from the previous quarter
The debt is 98% less than the equity
The debt to equity has dropped by 50% year-on-year
The equity has grown by 45% YoY but it has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.